Clostridioides difficile infection is a common cause of diarrhea in both the hospital and community settings, with C. difficile recurrence one of the most challenging outcomes to address. This article focuses on the factors that predict long-term complications of C. difficile infection and what can be done in clinical practice to minimize them (Part 5).

November, Clostridioides difficile infection awareness month

11 Nov 2022

by Konstantina Zafeiropoulou

Just one month before friends and families gather around the Christmas table, November is here to bring awareness around Clostridioides difficile infection, and the importance of microbiota-derived treatments. With this post, all of us in GMFH aim to highlight the importance of protecting ourselves and families and stopping the spread of this potentially deadly infection.

Correcting the altered gut microbiome is an important goal in Clostridioides difficile management, but the matter is not addressed by mainstream treatments with antibiotics. This article focuses on where fecal microbiota transplantation and investigational microbiota-based therapeutics stand for C. difficile infection (Part 3)

In a series of 7 webinar this programme will develop a full picture of the C. difficile infection (CDI) reaching from the importance of a healthy gut microbiota, to its detection and testing methods to current and future therapeutic approaches.

Clostridioides difficile infection is the most frequent cause of antibiotic-associated diarrhea in the hospital setting that has increased in severity. This article looks at the risk factors for developing C. difficile-associated disease, the spectrum of manifestations and the impact of the COVID-19 pandemic on the occurrence of C. difficile infection.

As we look back, we can certainly say that 2021 has been a productive year for gut microbiome research. In this last post of the year, we bring you key articles from our blog and studies on major advances in the role of the gut microbiome in maintaining health and helping to manage gut and immune-related diseases. We will also look at the therapeutic potential of probiotics, prebiotics and postbiotics for your clinical practice.